OTCMKTS:STDAF - STADA Arzneimittel Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 06/24/2019 09:14 AM ET)
Today's Range
Now: $90.37
50-Day Range
MA: $92.69
52-Week Range
Now: $90.37
Average Volume20 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates in two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxon for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Omeprazol for gastric ulcer/reflux. Read More…

Industry, Sector and Symbol

Industry Medicinals & botanicals
Previous SymbolNASDAQ:STDAF



Sales & Book Value

Annual Sales$2.61 billion



Next Earnings Date6/27/2019 (Estimated)
OptionableNot Optionable

Receive STDAF News and Ratings via Email

Sign-up to receive the latest news and ratings for STDAF and its competitors with MarketBeat's FREE daily newsletter.

STADA Arzneimittel (OTCMKTS:STDAF) Frequently Asked Questions

What is STADA Arzneimittel's stock symbol?

STADA Arzneimittel trades on the OTCMKTS under the ticker symbol "STDAF."

When is STADA Arzneimittel's next earnings date?

STADA Arzneimittel is scheduled to release their next quarterly earnings announcement on Thursday, June 27th 2019. View Earnings Estimates for STADA Arzneimittel.

Has STADA Arzneimittel been receiving favorable news coverage?

News articles about STDAF stock have trended very negative on Monday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. STADA Arzneimittel earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for STADA Arzneimittel.

Who are some of STADA Arzneimittel's key competitors?

Who are STADA Arzneimittel's key executives?

STADA Arzneimittel's management team includes the folowing people:
  • Mr. Mark Burgess Keatley MBA, MA, MPhil, CFO & Member of Exec. Board (Age 62)
  • Mr. Peter Goldschmidt, Chairman of the Exec. Board & CEO (Age 55)
  • Mr. Miguel Pagan Fernandez, CTO & Member of Exec. Board (Age 54)
  • Mr. Sebastian Kramer-Bach, Exec. VP of Corp. Communication (Age 44)
  • Ms. Kay Reubelt, Director of Investor Relations

How do I buy shares of STADA Arzneimittel?

Shares of STDAF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is STADA Arzneimittel's stock price today?

One share of STDAF stock can currently be purchased for approximately $90.37.

What is STADA Arzneimittel's official website?

The official website for STADA Arzneimittel is http://www.stada.de/.

How can I contact STADA Arzneimittel?

STADA Arzneimittel's mailing address is Stadastrasse 2-18, Bad Vilbel 2M, 61118. The company can be reached via phone at 49-6101-6030.

MarketBeat Community Rating for STADA Arzneimittel (OTCMKTS STDAF)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  240 (Vote Outperform)
Underperform Votes:  342 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about STADA Arzneimittel and other stocks. Vote "Outperform" if you believe STDAF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STDAF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel